1. Doyle P, Düren C, Nerlich K, Verburg FA, Grelle I, Jahn H, Fassnacht M, Mäder U, Reiners C, Luster M. Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adults. J Clin Endocrinol Metab. 2009; 94:2970-2974.
  2. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2009; 94:4171-4179.
  3. Király FJ, Kletting P, Reske SN, Glatting G. Modelling radioimmunotherapy with anti-CD45 antibody to obtain a more favourable biodistribution. Nuklearmedizin 2009; 48:113-119.
  4. Kletting P, Bunjes D, Reske SN, Glatting G. Improving anti-CD45 antibody radioimmunotherapy using a physiologically based pharmacokinetic model. J. Nucl. Med. 2009; 50:296-302.
  5. Kletting P, Glatting G. Model selection and inference in pharmacokinetics: The corrected Akaike information criterion and the F-test. Z. Med. Phys. 2009; 19:200-206.
  6. Kletting P, Kull T, Reske SN, Glatting G. Comparing time activity curves using the Akaike information criterion. Phys. Med. Biol. 2009; 54:N501-N507.
  7. Krüger S, Buck AK, Mottaghy FM, Hasenkamp E, Pauls S, Schumann C, Wibmer T, Merk T, Hombach V, Reske SN. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2009; 36:1807-1812.
  8. Hänscheid H, Lassmann M, Luster M, Kloos RT, Reiners C. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. Endocr Relat Cancer 2009; 16:1283-1289.
  9. Luster M, Schlumberger M, Pacini F. Comment on: Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective. Eur J Nucl Med Mol Imaging 2009; 36:329-330.
  10. Luster M, Handkiewicz-Junak D, Grossi A, Zacharin M, Taïeb D, Cruz O, Hitzel A, Casas JA, Mäder U, Dottorini ME. Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study. J Clin Endocrinol Metab. 2009; 94:3948-3953.
  11. Mutschler J, Steinbach G, Bunjes D, Reske SN, Buchmann I. Myeloablative radioimmunotherapy with 188Re-CD66 mAb before stem cell transplantion. No increase of proinflammatory cytokine levels of TNF-α. Nuklearmedizin 2009; 48:30-36.
  12. Reske SN. PET und PET/CT maligner Tumoren des exokrinen Pankreas. Radiologe 2009; 49:131-136.
  13. Reske SN. Multimodale molekulare Bildgebung des Prostatakarzinoms. Der Nuklearmediziner 2009; 32:105-114.
  14. Rinnab L, Simon J, Hautmann RE, Cronauer MV, Hohl K, Buck AK, Reske SN, Mottaghy FM. [11C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol 2009; 27:619-625.
  15. Shen C, Liu W, Buck AK, Reske SN. Pro-apoptosis and Anti-proliferation Effects of a Recombinant Dominant-negative Survivin-T34A in Human Cancer Cells. Anticancer Res. 2009; 29:1423-1428.
  16. Verburg FA, Mäder U, Luster M, Reiners C. Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases. Eur J Endocrinol 2009; 160:619-624.
  17. Verburg FA, Dietlein M, Lassmann M, Luster M, Reiners C. Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2009; 36:343-346.
  18. Verburg FA, Mäder U, Luster M, Reiners C. Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma. Clin Endocrinol 2009; 71:291–297.
  19. Verburg FA, Gasser M, Beissert M, Geissinger E, Luster M, Reiners C. Intratracheal growth of recurrent benign goiter. Thyroid 2009; 19:1009-1011.
  20. Zlatopolskiy B, Morgenroth A, Urusova EA, Dinger C, Kull T, Pape M, Glatting G, Reske SN. Towards to hENT1-nucleoside transporter selective imaging agents. Synthesis and in vitro evaluation of the radiolabeled SAENTA analogues. Bioorg Med Chem Lett 2009; 19:5151-5154.
  21. Zlatopolskiy BD, Morgenroth A, Kunkel FH-G, Urusova EA, Dinger C, Kull T, Lepping C, Reske SN. Synthesis and Biologic Study of IV-14, a New Ribonucleoside Radiotracer for Tumor Visualization. J Nucl Med 2009; 50:1895-1903.